Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Study
— Study Results Further Support Advancement of SYN-005 into Clinical Trials for Treatment and Prevention of Pertussis — — Poster Presentations Planned for ECCMID and ESPID Conferences, Including Data from Prophylaxis Study — ROCKVILLE, Md., April 19, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome […]